TOP ROW FROM LEFT TO RIGHT: Richard Parsons Financial Controller, Sarah Hale Senior Scientist, Analytical Development, Pippa Rathbone Executive Administrator, Vesa Qarkaxhija Associate Study Manager, Lawrence Petherbridge Research Associate, Molecular Virology, Elizabeth Eagling-Vose Head of Clinical Operations, Asaduzzaman Forazi MD Senior Scientist, Process Development, Dr. Tom Evans Chief Scientific Officer, Angela Robinson Research Associate, Analytical Development, Alison Turner Director, Process Development, Jamie Comley Laboratory Technician, Vicky Wheeler Programme Manager, Chris Ellis Chief Operating Officer, Benaka Karanth Clinical Study Manager, Linda Kelly Programme Manager, Karen Goode Regulatory Affairs Manager.
BOTTOM ROW FROM LEFT TO RIGHT: Denise McCarron Senior Clinical Trials Administrator, Helen Ball Accountant, Guilherme Stahlberg Research Associate, Molecular Virology, Kinga Piotrowska Research Associate, Early Development Lab/Process Development, Barsha Thapa Research Associate, Early Development Lab/Process Development, Shakanna Muruganandan Research Associate, Early Development Lab/Analytics, Bill Enright Chief Executive Officer, Graham Griffiths Chief Business Officer, Dan Jones Senior Scientist, Molecular Virology, Louise Bussey Senior Clinical Study Manager, Henry Hodge Business Development Associate, Frederick Momoh Research Associate, Early Development Lab/Process Development, Gwen Tucker Clinical Study Manager, Stella Ackrell Programme Manager, Manufacturing, Rosa Fortes Administrator.
NOT PRESENT: Sarah Sebastian Director of Virology, Bernie McDonald Head of IP, Tomas Bailey Project Coordinator, Sophie Jamieson Part-time Research Associate, Process Development, Raisha Kennerly Senior Clinical Trials Assistant, Henrik Sorensen Director Programme Lead, Megan Marshall Chief Medical Officer, Georgy Egorov Chief Financial Officer, Simon Alvis Vice President of Manufacturing
Chief Executive Officer & Board Director
William “Bill” Enright is a seasoned biotech executive with more than thirty years of experience in building and financing both privately held and publicly held companies. Bill spent more than ten years at Altimmune (NASDAQ: ALT) as a Director, President & CEO, moving multiple programs into clinical testing, completing several acquisitions and eventually taking the company public. Prior to joining Altimmune, Bill spent six years with GenVec, Inc. (acquired by Intrexon) with increasing responsibilities, which included a role as Head of Business Development. Bill has raised more than $300 million through private, public and non-dilutive financings.
Bill brings a breadth of experiences in a variety of positions within the life science/biotech industry, including time as a consultant, a bench scientist and 12 years with Life Technologies, Inc. (acquired by Thermo-Fisher), working in various senior level licensing, business management, manufacturing and research roles.
Bill received a Master of Arts in Molecular Biology from SUNY at Buffalo and a Master of Science in Business Management from Johns Hopkins University.
Chief Scientific Officer & Board Director
Dr. Thomas G. Evans
Tom established a laboratory during his first position at the University of Utah and directed the HIV clinic. He moved to the University of Rochester as Associate Professor for 5 years, before becoming Infectious Diseases Division Chief and tenured full Professor at the University of California, Davis. His academic research centered on leishmania and HIV vaccine development and led to him joining Vical, a DNA vaccine developer as Chief Medical Officer in 2002. In 2005 he joined the Novartis Institutes for Biomedical Research as Global Head of Infectious Diseases Translational Medicine and Research. In September 2008 he moved to Shanghai as VP for Translational Sciences in Asia for Novartis. In September 2010, Tom joined Aeras, a non-profit Product Development Partnership with a mission to develop global tuberculosis vaccines, as the Chief Scientific Officer, and became CEO in February 2013. He has over 150 authored publications.
Tom joined Vaccitech in the spring of 2016. Having successfully built Vaccitech to a late clinical stage biopharmaceutical company as CEO, in his role as CSO, Tom focuses more specifically on the science, research and development that underpin Vaccitech’s next generation T cell induction products.
Chief Medical Officer
Dr. Meg Marshall
Dr. Margaret (Meg) Marshall has more than 25 years of experience in the preclinical and clinical development of cell and antibody-based immunotherapy for infectious disease and cancer, including vaccines, checkpoint inhibitors, and cell therapies such as CAR T cells. Prior to joining Vaccitech, she held directorship positions in the clinical research departments of Kyowa Kirin, Kite Pharma and Pfizer Oncology.
Meg received her MD from the University of California at San Diego and trained in Paediatrics at the University of Washington/ Seattle Children’s Hospital, followed by a postdoctoral fellowship in the Laboratory of Molecular Immunogenetics and Vaccine Research Section at the National Cancer Institute in Bethesda MD. Meg joined Vaccitech in 2020.
Graham joined Vaccitech as Chief Business Officer in October 2017. Previously he was COO and co-founder of Agalimmune Limited, a clinical stage Biotech developing directly administered immunotherapies for oncology indications.
Graham qualified as a solicitor in London in 2005, before moving to co-found technology company MET, which was subsequently sold to a group of private investors. He was an investment fund manager at Matrix Securities and then worked for 9 years as an operator and investor to develop a portfolio of life sciences companies held by Animatrix Capital LLP. Graham’s focus has been on operating and developing early stage products and companies targeting the diagnosis and treatment of cancer and infectious diseases. One of these was Agalimmune, where Graham led the licensing, funding and development of a novel cancer immunotherapy and played a lead role in the company’s successful sale to NASDAQ-listed BioLineRx in 2017. Graham holds a BA Hons degree in Law with French from Newcastle University.
Chief Financial Officer
Georgy has over 20 years of senior finance, strategy, investment banking and capital markets experience as well as extensive knowledge of investor relations and corporate development.
In 2020, Georgy joined Vaccitech from Exscientia, one of the global leaders of AI drug discovery, where he was CFO and Board member. During his investment banking career at Goldman Sachs and UBS, he helped raise more than $100B of equity and debt capital for globally leading companies and was involved in numerous M&A transactions.
Co-Founder & Scientific Advisor
Professor Adrian Hill
Professor Sarah Gilbert
Professor Gilbert is Professor of Vaccinology at the University of Oxford and leads programmes on the development of vaccines against multiple emerging viral pathogens as well as research into vaccine manufacturing. She is the Oxford Project Lead for the Oxford/AstraZeneca Covid-19 vaccine project.
She is an acknowledged expert in the preclinical and clinical development of viral vectored vaccines. Professor Gilbert’s chief research interest is the development of vaccines that work by inducing strong and protective T cell responses, in addition to working on the development of the viral vector platform technology and its application in rapid vaccine development for emerging pathogens.
Board of Directors
Robin Wright has extensive senior level experience as a CFO of public companies in both the pharmaceutical and biotechnology industries. He is a qualified accountant and currently Chief Financial Officer of the biopharmaceutical company Pharming Group NV in the Netherlands.
Robin joined Pharming from Sweden-based Karolinska Development AB (publ.) (KDEV: SS), where he was CFO and Head of Business Development. Mr. Wright was CFO and Head of Business Development at Orexo AB (publ.) (ORX: SS) in Sweden prior to this. Before going to Sweden, he worked in private equity and corporate finance advisory roles, including long periods at Citibank Salomon Smith Barney and Barclays de Zoete Wedd. He has completed over 170 global license and M&A transactions as well as several hundred financing transactions in debt and equity within the pharma/ biotech sector. Mr. Wright holds a BA degree in Chemistry from Oxford University and is a Fellow of the Institute of Chartered Accountants in England and Wales in the UK.
Alex is Head of Corporate Finance at OSI and a former physician. OSI is the £600m venture capital firm partnered with Oxford University to identify and develop the University’s science and technology into category defining companies.
Alex was a medical student and junior doctor in the Oxford training deanery before transitioning to investment banking. He has over 12 years’ experience in the healthcare and other investment banking sectors, including equity and debt capital raisings, mergers and acquisitions as well as licensing transactions gained at UBS and Lazard. Alex holds a BA in Physiological Sciences and a BM BCh from Oxford University.
Pierre A Morgon
Pierre is CEO of MRGN Advisors, Regional Partner for Switzerland at Mérieux Equity Partners and Senior Vice President International Business at CanSino Biologics. He is Chairman of the Boards of Theradiag, Eurocine Vaccines, MYCB1 and Health Technologies Holding, as well as Non-Executive Director to the Boards of Vaccitech and Univercells.
Pierre has over 30 years of experience in the global life science industry, especially with specialty care, vaccines and immunotherapy, at the helm of international operations, in C-level positions at global level in multinational corporations and as CEO of start-up companies. He is a lecturer in several MBA programs and in life science conferences, and at the Mass Challenge incubator in Switzerland where he is also a mentor for start-up life sciences companies. He holds a Doctorate of Pharmacy, a Master in Business Law and a MBA. He is also an alumnus of INSEAD and IMD.
Scientific Advisory Board
Steve Dewhurst PhD
He is a former member of the NIH Recombinant Advisory Committee (RAC), the past President of a start-up vaccine company (Codevax), and the current director of the UR’s Upstate Stem Cell cGMP Facility – which supports the development of cGMP-compliant cell production methods and the manufacturing of cell-based products for clinical trial. He joined the UR in 1990 and has over 25 years’ experience as a molecular virologist, working principally on HIV and the influenza virus.
Benoit Van den Eynde
Patricia Fast, MD, Ph.D.
Jerome H. Kim, MD
IVI’s oral cholera vaccine, prequalified by Sanofi and EuBiologics, is used around the world to prevent that deadly diarrheal disease. IVI’s typhoid conjugate vaccine is entering Phase II testing by two vaccine companies. Dr Kim is a graduate with high honors and highest honors in History and Biology, respectively, from the University of Hawaii, and received an MD degree from Yale University School of Medicine. Prior to IVI, Dr. Kim led the Army’s advanced development program for HIV vaccines, the RV144 HIV vaccine trial and correlates analysis, and a molecular virology laboratory at Walter Reed Army Institute of Research.
Drew Pardoll, MD, PhD
He is the Director of the Bloomberg Kimmel Institute for Cancer Immunotherapy and Director of the Cancer Immunology Program at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. Dr. Pardoll attended Johns Hopkins University, where he earned his M.D., Ph.D., in 1982 and completed his Medical Residency and Oncology Fellowship in 1985. He then worked for three years at the National Institutes of Health as a Medical Staff Fellow. Dr. Pardoll joined the departments of oncology and medicine in 1988. Over the past two decades, Dr. Pardoll has studied molecular aspects of dendritic cell biology and immune regulation, particularly related to mechanisms by which cancer cells evade elimination by the immune system. He is an inventor of a number of immunotherapies, including GVAX cancer vaccines and Listeria monocytogenes-based cancer vaccines. Dr. Pardoll’s basic immunology discoveries include the identification of γδ-T cells, NKT cells and IKDC. He elucidated the role of Stat3 signaling in tumor immune evasion and in Th17 development, leading to the discovery that Stat3-driven Th17 responses promote carcinogenesis. Dr. Pardoll discovered one of the two ligands for the PD-1 inhibitory receptor and leads the Hopkins cancer immunology program that developed PD-1 pathway-targeted antibodies, demonstrating their clinical activity in multiple cancer types.